Is Rosiglitazone as Safe as BARI 2D and the Reanalysls of RECORD Imply?

摘要

Rosiglitazone is an antidiabetic substance and primarily activates PPAR-gamma (peroxisome proliferator-ac-tivated receptor). Activation of this receptor has several effects, one of them being an improvement in insulin resistance. Rosiglitazone was put under selling restrictions in the USA and was withdrawn from the market in Europe in 2010 due to an increased risk of cardiovascular events. In addition, it had been on the market for about 10 years when claims about increased myocardial infarction rates emerged, leading to an ongoing controversy. Very recent data have been used to challenge this safety concern.